Cancer in the elderly: Tailoring treatment

Hospital Practice

Volumn 35, Issue 3, 2000, Pages 73-80

  Balducci, Lodovico ^a,c,d   Carbone, Paul P ^b,e  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF WISCONSIN   (United States)

^c H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; TAMOXIFEN; VINCRISTINE;

AGED; BREAST CANCER; CANCER CHEMOTHERAPY; CASE REPORT; DAILY LIFE ACTIVITY; DRUG INDUCED DISEASE; FEMALE; GERIATRIC PATIENT; HUMAN; LIVER METASTASIS; LUNG CANCER; MALE; MEDICAL DECISION MAKING; NEUTROPENIA; NONHODGKIN LYMPHOMA; ONCOLOGY; PATIENT CARE; REVIEW;

EID: 0034653545     PISSN: 87502836     EISSN: None     Source Type: Journal    
DOI: 10.3810/hp.2000.03.187     Document Type: Review

References (8)

1. Balducci L, Extermann M. Cancer chemotherapy in the older patient What the medical oncologist needs to know. Cancer 80:1317, 1997
2. Bates T et al. Breast cancer in elderly women: A cancer research campaign trial comparing treatment with tamoxifen and optimal surgery with tamoxifen alone. The Elderly Breast Cancer Working Party, Br J Surg 78:591, 1991
3. Demetri GD et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: Results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 16:3412, 1998
4. Gomez H et al. Elderty patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: Identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 16:2352, 1998
5. Pierelli L et al. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral blood progenitor-cell mobilization after epirubicin, paclrtaxel and cisplatin combination chemotherapy: Results of a randomized trial. J Clin Oncol 17:1288, 1999
6. Saltzstein SL, Behling CA, Baergen RN. Features of cancer in nonagenarians and centenarians. J Am Geriatr Soc 46:994, 1998
7. Tirelli U et al. CHOP is the standard regimen in patients ≥70 years of age with intermediate-grade and high-grade non-Hodgkin's Iymphoma: Results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group. J Clin Oncol 16:27, 1998
8. Zinzani PL et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's Iymphoma. Blood 89:3974, 1997